Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Daiichi Sankyo RD Novare (Japan)
Alternate name:
第一三共RDノバーレ
Parent institution:
Daiichi-Sankyo (Japan)
ROR:
03ey07j79
OpenAlex ID:
I4405284387
Works
291
Awards
1
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
2016
·
Yusuke Ogitani
, Tetsuo Aida
, et al.
·
Clinical Cancer Research
·
1,253
A metabolic pathway for bile acid dehydroxylation by the gut microbiome
2020
·
Masanori Funabashi
, Tyler L. Grove
, et al.
·
Nature
·
610
PDF
A gut-derived metabolite alters brain activity and anxiety behaviour in mice
2022
·
Brittany D. Needham
, Masanori Funabashi
, et al.
·
Nature
·
499
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
2023
·
Fernanda Mosele
, Elise Deluche
, et al.
·
Nature Medicine
·
434
PDF
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
2021
·
Daisuke Okajima
, Satoru Yasuda
, et al.
·
Molecular Cancer Therapeutics
·
369
Medium-chain Fatty Acid-sensing Receptor, GPR84, Is a Proinflammatory Receptor
2013
·
Masakatsu Suzuki
, Sachiko Takaishi
, et al.
·
Journal of Biological Chemistry
·
234
PDF
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
2019
·
Ryohei Katayama
, Bo Gong
, et al.
·
Nature Communications
·
150
PDF
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
2017
·
Daisuke Honma
, Osamu Kanno
, et al.
·
Cancer Science
·
146
PDF
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
2023
·
Ian E. Krop
, Norikazu Masuda
, et al.
·
Journal of Clinical Oncology
·
144
PDF
Protective neutralizing influenza antibody response in the absence of T follicular helper cells
2016
·
Kosuke Miyauchi
, Akiko Sugimoto-Ishige
, et al.
·
Nature Immunology
·
142
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
2015
·
Kiyoshi Arai
, Tsuyoshi Homma
, et al.
·
European Journal of Pharmacology
·
140
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
2024
·
Kohei Shitara
, Yung-Jue Bang
, et al.
·
Nature Medicine
·
126
Mechanisms of action and resistance in histone methylation-targeted therapy
2024
·
Makoto Yamagishi
, Yuta Kuze
, et al.
·
Nature
·
125
PDF
SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors
2015
·
Shivani Malik
, Lidia Villanova
, et al.
·
Scientific Reports
·
120
PDF
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
2020
·
Kyriakos P. Papadopoulos
, Erkut Borazanci
, et al.
·
Clinical Cancer Research
·
118
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2021
·
Kimio Yonesaka
, Junko Tanizaki
, et al.
·
Clinical Cancer Research
·
106
PDF
DS16570511 is a small-molecule inhibitor of the mitochondrial calcium uniporter
2017
·
Naohiro Kon
, Michiko Murakoshi
, et al.
·
Cell Death Discovery
·
103
PDF
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
2022
·
Michiko Yamato
, Jun Hasegawa
, et al.
·
Molecular Cancer Therapeutics
·
100
Cryo-EM Structure of K+-Bound hERG Channel Complexed with the Blocker Astemizole
2021
·
Tatsuki Asai
, Naruhiko Adachi
, et al.
·
Structure
·
99
TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells
2017
·
Shin-Ichiroh Saitoh
, Fumiko Abe
, et al.
·
Nature Communications
·
98
PDF
Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity
2019
·
Junya Kawai
, Tadashi Toki
, et al.
·
Journal of Medicinal Chemistry
·
95
Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches
2018
·
Kazuishi Kubota
, Masanori Funabashi
, et al.
·
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
·
81
Inhibiting RORγt/Th17 axis for autoimmune disorders
2014
·
Fujio Isono
, Saori Fujita-Sato
, et al.
·
Drug Discovery Today
·
79
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
2022
·
Ian E. Krop
, Norikazu Masuda
, et al.
·
Journal of Clinical Oncology
·
68
Ceramide kinase deficiency improves diet‐induced obesity and insulin resistance
2012
·
Susumu Mitsutake
, Tomomi Date
, et al.
·
FEBS Letters
·
68
Show more works
View as search
Works count:
291
Citation count:
16,840
Year
Topic
Type
